A Novartis drug has been shown to reduce risk of disability progression in secondary progressive multiple sclerosis, an advanced form of the disease. The Swiss pharma said the phase 3 EXPAND study ...

On Tuesday, Novartis AG (NYSE:NVS) reported third-quarter sales of $12.823 billion, up 9% (+10% on constant currency), ...

Novartis sees promise in a Monte Rosa drug candidate designed to degrade a protein associated with autoimmune disease and the pharmaceutical giant is paying $150 million for global rights to the ...

Novartis is paying $150 million for a closer look at Schrödinger’s catalog of programs. The Big Pharma will work with Schrödinger to advance some of the computing-enabled R&D shop’s discovery programs ...

Oct 16 (Reuters) - Novartis (NOVN.S), opens new tab has lost a bid to keep a generic version of its top-selling heart failure drug Entresto off the U.S. market by blocking regulators from ...

LONDON — Novartis on Tuesday increased its earnings guidance for the third time this year, boosted by strong sales of its leading drugs. The company said it anticipates full-year operating ...

Novartis NOVN-0.15%decrease ... boosted by revenue from its blockbuster drugs. The Swiss pharmaceutical giant said Tuesday that it now expects its core operating profit—one of its preferred ...

Novartis AG’s best-selling drug and a key new cancer medicine posted disappointing sales last quarter, even as the Swiss drugmaker lifted profit guidance for a third straight quarter. Sales of ...

Schrodinger (SDGR) today announced a research collaboration and license agreement with Novartis (NVS) to advance multiple development ...

Multiple sclerosis drug Kesimpta sales reached $838 million, up +28%, reflecting increased demand for a high-efficacy product with convenient self-administered dosing. Guidance: Novartis also ...